Potentiating the cellular targeting and anti-tumor activity of Dp44mT via binding to human serum albumin: Two saturable mechanisms of Dp44mT uptake by cells

Oncotarget

Volumn 6, Issue 12, 2015, Pages 10374-10398

  Merlot, Angelica M ^a   Sahni, Sumit ^a   Lane, Darius J R ^a   Fordham, Ashleigh M ^a   Pantarat, Namfon ^a   Hibbs, David E ^a   Richardson, Vera ^a   Doddareddy, Munikumar R ^a   Ong, Jennifer A ^a   Huang, Michael L H ^a   Richardson, Des R ^a   Kalinowski, Danuta S ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Albumin; Anti tumor targeting; Dp44mT; Human serum albumin

Indexed keywords

2 BENZOYLPYRIDINE 4 ETHYL 3 THIOSEMICARBAZONE; CARBON 14; DI 2 PYRIDYLKETONE 4,4 DIMETHYL 3 THIOSEMICARBAZONE; HUMAN SERUM ALBUMIN; PYRIDOXAL ISONICOTINOYLHYDRAZONE; THIOSEMICARBAZONE DERIVATIVE; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; DI-2-PYRIDYLKETONE-4,4-DIMETHYL-3-THIOSEMICARBAZONE; SERUM ALBUMIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CELL TRANSPORT; CIRCULAR DICHROISM; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG BINDING; DRUG BINDING SITE; DRUG DIFFUSION; DRUG POTENTIATION; DRUG STRUCTURE; DRUG TARGETING; DRUG UPTAKE; HUMAN; HUMAN CELL; LIGAND BINDING; MOLECULAR DOCKING; PHOTOCHEMICAL QUENCHING; STRUCTURE ACTIVITY RELATION; APOPTOSIS; CELL MOTION; DRUG EFFECTS; DRUG SCREENING; HEP-G2 CELL LINE; MCF-7 CELL LINE; METABOLISM; MOLECULAR MODEL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; DRUG SCREENING ASSAYS, ANTITUMOR; HEP G2 CELLS; HUMANS; MCF-7 CELLS; MODELS, MOLECULAR; SERUM ALBUMIN; THIOSEMICARBAZONES;

EID: 84929587196     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3606     Document Type: Article

References (93)

1. Pinkerton TC and Koeplinger KA. Determination of warfarin-human serum albumin protein binding parameters by an improved Hummel-Dreyer high-performance liquid chromatographic method using internal surface reversedphase columns. Anal Chem. 1990; 62: 2114-2122.
2. Kragh-Hansen U. Molecular aspects of ligand binding to serum albumin. Pharmacol Rev. 1981; 33: 17-53.
3. Richieri GV, Anel A and Kleinfeld AM. Interactions of long-chain fatty acids and albumin: determination of free fatty acid levels using the fluorescent probe ADIFAB. Biochemistry. 1993; 32: 7574-7580.
4. Ramsey BL and Westphal U. Steroid-protein interactions. 40. The effect of fatty acids on progesterone binding to human serum albumin. Biochim Biophys Acta. 1978; 529: 115-122.
5. Peters T: All about albumin. California, Academic Press Inc., 1996.
6. Masuoka J, Hegenauer J, Van Dyke BR and Saltman P. Intrinsic stoichiometric equilibrium constants for the binding of zinc(II) and copper(II) to the high affinity site of serum albumin. J Biol Chem. 1993; 268: 21533-21537.
7. Vuignier K, Schappler J, Veuthey JL, Carrupt PA and Martel S. Drug-protein binding: a critical review of analytical tools. Anal Bioanal Chem. 2010; 398: 53-66.
8. van der Veldt AA, Luurtsema G, Lubberink M, Lammertsma AA and Hendrikse NH. Individualized treatment planning in oncology: role of PET and radiolabelled anticancer drugs in predicting tumour resistance. Curr Pharm Des. 2008; 14: 2914-2931.
9. Lancon A, Delmas D, Osman H, Thenot JP, Jannin B and Latruffe N. Human hepatic cell uptake of resveratrol: involvement of both passive diffusion and carrier-mediated process. Biochem Biophys Res Commun. 2004; 316: 1132-1137.
10. Trigatti BL and Gerber GE. A direct role for serum albumin in the cellular uptake of long-chain fatty acids. Biochem J. 1995; 308 ( Pt 1): 155-159.
11. van der Vusse GJ. Albumin as fatty acid transporter. Drug Metab Pharmacokinet. 2009; 24: 300-307.
12. Pardridge WM and Fierer G. Transport of tryptophan into brain from the circulating, albumin-bound pool in rats and in rabbits. J Neurochem. 1990; 54: 971-976.
13. Pardridge WM and Mietus LJ. Transport of steroid hormones through the rat blood-brain barrier. Primary role of albumin-bound hormone. J Clin Invest. 1979; 64: 145-154.
14. Manni A, Pardridge WM, Cefalu W, Nisula BC, Bardin CW, Santner SJ and Santen RJ. Bioavailability of albuminbound testosterone. J Clin Endocrinol Metab. 1985; 61: 705-710.
15. Matsumura Y and Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986; 46: 6387-6392.
16. Carmeliet P and Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000; 407: 249-257.
17. Greish K. Enhanced permeability and retention of macromolecular drugs in solid tumors: a royal gate for targeted anticancer nanomedicines. J Drug Target. 2007; 15: 457-464.
18. Merlot AM, Kalinowski DS and Richardson DR. Novel Chelators for Cancer Treatment: Where Are We Now? Antioxid Redox Signal. 2013; 18: 973-1006.
19. Buss JL, Torti FM and Torti SV. The role of iron chelation in cancer therapy. Curr Med Chem. 2003; 10: 1021-1034.
20. Yen Y, Margolin K, Doroshow J, Fishman M, Johnson B, Clairmont C, Sullivan D and Sznol M. A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother Pharmacol. 2004; 54: 331-342.
21. Wadler S, Makower D, Clairmont C, Lambert P, Fehn K and Sznol M. Phase I and pharmacokinetic study of the ribonucleotide reductase inhibitor, 3-aminopyridine-2- carboxaldehyde thiosemicarbazone, administered by 96- hour intravenous continuous infusion. J Clin Oncol. 2004; 22: 1553-1563.
22. Kalinowski DS and Richardson DR. The evolution of iron chelators for the treatment of iron overload disease and cancer. Pharmacol Rev. 2005; 57: 547-583.
23. Richardson DR, Sharpe PC, Lovejoy DB, Senaratne D, Kalinowski DS, Islam M and Bernhardt PV. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity. J Med Chem. 2006; 49: 6510-6521.
24. Whitnall M, Howard J, Ponka P and Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A. 2006; 103: 14901-14906.
25. Yuan J, Lovejoy DB and Richardson DR. Novel di-2- pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood. 2004; 104: 1450-1458.
26. Kovacevic Z, Chikhani S, Lovejoy DB and Richardson DR. Novel thiosemicarbazone iron chelators induce upregulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer. Mol Pharmacol. 2011; 80: 598-609.
27. Liu W, Xing F, Iiizumi-Gairani M, Okuda H, Watabe M, Pai SK, Pandey PR, Hirota S, Kobayashi A, Mo YY, Fukuda K, Li Y and Watabe K. N-myc downstream regulated gene 1 modulates Wnt-beta-catenin signalling and pleiotropically suppresses metastasis. EMBO Mol Med. 2012; 4: 93-108.
28. Sun J, Zhang D, Zheng Y, Zhao Q, Zheng M, Kovacevic Z and Richardson DR. Targeting the metastasis suppressor, NDRG1, using novel iron chelators: regulation of stress fiber-mediated tumor cell migration via modulation of the ROCK1/pMLC2 signaling pathway. Mol Pharmacol. 2013; 83: 454-469.
29. Chen Z, Zhang D, Yue F, Zheng M, Kovacevic Z and Richardson DR. The iron chelators Dp44mT and DFO inhibit TGF-beta-induced epithelial-mesenchymal transition via up-regulation of N-Myc downstream-regulated gene 1 (NDRG1). J Biol Chem. 2012; 287: 17016-17028.
30. Bernhardt PV, Sharpe PC, Islam M, Lovejoy DB, Kalinowski DS and Richardson DR. Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity. J Med Chem. 2009; 52: 407-415.
31. Lovejoy DB, Jansson PJ, Brunk UT, Wong J, Ponka P and Richardson DR. Antitumor activity of metal-chelating compound Dp44mT is mediated by formation of a redoxactive copper complex that accumulates in lysosomes. Cancer Res. 2011; 71: 5871-5880.
32. Yu Y, Suryo Rahmanto Y, Hawkins CL and Richardson DR. The potent and novel thiosemicarbazone chelators di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone and 2-benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone affect crucial thiol systems required for ribonucleotide reductase activity. Mol Pharmacol. 2011; 79: 921-931.
33. Le NT and Richardson DR. Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation. Blood. 2004; 104: 2967-2975.
34. Merlot AM, Pantarat N, Menezes SV, Sahni S, Richardson DR and Kalinowski DS. Cellular uptake of the antitumor agent Dp44mT occurs via a carrier/receptor-mediated mechanism. Mol Pharmacol. 2013; 84: 911-924.
35. Merlot AM, Pantarat N, Lovejoy DB, Kalinowski DS and Richardson DR. Membrane transport and intracellular sequestration of novel thiosemicarbazone chelators for the treatment of cancer. Mol Pharmacol. 2010; 78: 675-684.
36. Merlot AM, Kalinowski DS and Richardson DR. Unraveling the mysteries of serum albumin-more than just a serum protein. Front Physiol. 2014; 5: 299.
37. Richardson DR, Tran EH and Ponka P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood. 1995; 86: 4295-4306.
38. Kalinowski DS, Yu Y, Sharpe PC, Islam M, Liao YT, Lovejoy DB, Kumar N, Bernhardt PV and Richardson DR. Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents. J Med Chem. 2007; 50: 3716-3729.
39. Dang X, Liu Q, Cui F, Qin L, Zhang G, Yao X and Du J. An improved synthetic approach to 7-[3-amino-4-O-(alphal- mycarosyl)-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl] daun orubicinone and its interaction with human serum albumin. Carbohydr Res. 2011; 346: 949-955.
40. Das P, Mallick A, Haldar B, Chakrabarty A and Chattopadhyay N. Fluorescence resonance energy transfer from tryptophan in human serum albumin to a bioactive indoloquinolizine system. J Chem Sci. 2007; 119: 77-82.
41. Francis GL. Albumin and mammalian cell culture: implications for biotechnology applications. Cytotechnology. 2010; 62: 1-16.
42. He XM and Carter DC. Atomic structure and chemistry of human serum albumin. Nature. 1992; 358: 209-215.
43. Ahmad B, Ahmed MZ, Haq SK and Khan RH. Guanidine hydrochloride denaturation of human serum albumin originates by local unfolding of some stable loops in domain III. Biochim Biophys Acta. 2005; 1750: 93-102.
44. Baker E, Richardson D, Gross S and Ponka P. Evaluation of the iron chelation potential of hydrazones of pyridoxal, salicylaldehyde and 2-hydroxy-1-naphthylaldehyde using the hepatocyte in culture. Hepatology. 1992; 15: 492-501.
45. Nicholson JP, Wolmarans MR and Park GR. The role of albumin in critical illness. Br J Anaesth. 2000; 85: 599-610.
46. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, Repasky MP, Knoll EH, Shelley M, Perry JK, Shaw DE, Francis P and Shenkin PS. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004; 47: 1739-1749.
47. Ghuman J, Zunszain PA, Petitpas I, Bhattacharya AA, Otagiri M and Curry S. Structural basis of the drug-binding specificity of human serum albumin. J Mol Biol. 2005; 353: 38-52.
48. Makey DG and Seal US. The detection of four molecular forms of human transferrin during the iron binding process. Biochim Biophys Acta. 1976; 453: 250-256.
49. Karin M and Mintz B. Receptor-mediated endocytosis of transferrin in developmentally totipotent mouse teratocarcinoma stem cells. J Biol Chem. 1981; 256: 3245-3252.
50. Richardson D and Baker E. Two mechanisms of iron uptake from transferrin by melanoma cells. The effect of desferrioxamine and ferric ammonium citrate. J Biol Chem. 1992; 267: 13972-13979.
51. Richardson DR and Baker E. The uptake of iron and transferrin by the human malignant melanoma cell. Biochim Biophys Acta. 1990; 1053: 1-12.
52. Iacopetta BJ and Morgan EH. The kinetics of transferrin endocytosis and iron uptake from transferrin in rabbit reticulocytes. J Biol Chem. 1983; 258: 9108-9115.
53. Wiley HS and Kaplan J. Epidermal growth factor rapidly induces a redistribution of transferrin receptor pools in human fibroblasts. Proc Natl Acad Sci U S A. 1984; 81: 7456-7460.
54. Harding C, Heuser J and Stahl P. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol. 1983; 97: 329-339.
55. Podlecki DA, Smith RM, Kao M, Tsai P, Huecksteadt T, Brandenburg D, Lasher RS, Jarett L and Olefsky JM. Nuclear translocation of the insulin receptor. A possible mediator of insulin's long term effects. J Biol Chem. 1987; 262: 3362-3368.
56. Fritzsche T, Schnolzer M, Fiedler S, Weigand M, Wiessler M and Frei E. Isolation and identification of heterogeneous nuclear ribonucleoproteins (hnRNP) from purified plasma membranes of human tumour cell lines as albumin-binding proteins. Biochem Pharmacol. 2004; 67: 655-665.
57. O'Toole JF and Sedor JR. Are cubilin (CUBN) variants at the heart of urinary albumin excretion? J Am Soc Nephrol. 2011; 22: 404-406.
58. Podhajcer OL, Benedetti LG, Girotti MR, Prada F, Salvatierra E and Llera AS. The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host. Cancer Metastasis Rev. 2008; 27: 691-705.
59. Frei E. Albumin binding ligands and albumin conjugate uptake by cancer cells. Diabetol Metab Syndr. 2011; 3: 11.
60. Baines RJ, Chana RS, Hall M, Febbraio M, Kennedy D and Brunskill NJ. CD36 mediates proximal tubular binding and uptake of albumin and is upregulated in proteinuric nephropathies. Am J Physiol Renal Physiol. 2012; 303: F1006-1014.
61. Pawluczyk IZ, Pervez A, Ghaderi Najafabadi M, Saleem MA and Topham PS. The effect of albumin on podocytes: the role of the fatty acid moiety and the potential role of CD36 scavenger receptor. Exp Cell Res. 2014; 326: 251-258.
62. Schwegler H, Crusio WE, Lipp HP, Brust I and Mueller GG. Early postnatal hyperthyroidism alters hippocampal circuitry and improves radial-maze learning in adult mice. J Neurosci. 1991; 11: 2102-2106.
63. Zhai XY, Nielsen R, Birn H, Drumm K, Mildenberger S, Freudinger R, Moestrup SK, Verroust PJ, Christensen EI and Gekle M. Cubilin- and megalin-mediated uptake of albumin in cultured proximal tubule cells of opossum kidney. Kidney Int. 2000; 58: 1523-1533.
64. Lane DJ, Chikhani S, Richardson V and Richardson DR. Transferrin iron uptake is stimulated by ascorbate via an intracellular reductive mechanism. Biochim Biophys Acta. 2013; 1833: 1527-1541.
65. Richardson DR and Baker E. Two saturable mechanisms of iron uptake from transferrin in human melanoma cells: the effect of transferrin concentration, chelators, and metabolic probes on transferrin and iron uptake. J Cell Physiol. 1994; 161: 160-168.
66. van Schaik ML, Weening RS and Roos D. Phenylglyoxal is not a selective inhibitor of phagocytosis. J Cell Sci. 1979; 38: 331-343.
67. Ivanov AI. Exocytosis and endocytosis. Preface. Methods Mol Biol. 2008; 440: v-vi.
68. Morgan EH. Inhibition of reticulocyte iron uptake by NH4Cl and CH3NH2. Biochim Biophys Acta. 1981; 642: 119-134.
69. Richardson DR and Ponka P. The iron metabolism of the human neuroblastoma cell: lack of relationship between the efficacy of iron chelation and the inhibition of DNA synthesis. J Lab Clin Med. 1994; 124: 660-671.
70. Morgan EH. Transferrin, biochemistry, physiology and clinical significance. Mol Aspects Med. 1981; 4: 1-123.
71. Klausner RD, Ashwell G, van Renswoude J, Harford JB and Bridges KR. Binding of apotransferrin to K562 cells: explanation of the transferrin cycle. Proc Natl Acad Sci U S A. 1983; 80: 2263-2266.
72. Grant CM, MacIver FH and Dawes IW. Mitochondrial function is required for resistance to oxidative stress in the yeast Saccharomyces cerevisiae. FEBS Lett. 1997; 410: 219-222.
73. Morgan EH and Baker E. The effect of metabolic inhibitors on transferrin and iron uptake and transferrin release from reticulocytes. Biochim Biophys Acta. 1969; 184: 442-454.
74. Yumoto R, Suzuka S, Oda K, Nagai J and Takano M. Endocytic uptake of FITC-albumin by human alveolar epithelial cell line A549. Drug Metab Pharmacokinet. 2012; 27: 336-343.
75. Yumoto R, Suzuka S, Nishimoto S, Nagai J and Takano M. Enhancing effect of poly(amino acid)s on albumin uptake in human lung epithelial A549 cells. Drug Metab Pharmacokinet. 2013; 28: 497-503.
76. Decker P and Muller S. Modulating poly (ADP-ribose) polymerase activity: potential for the prevention and therapy of pathogenic situations involving DNA damage and oxidative stress. Curr Pharm Biotechnol. 2002; 3: 275-283.
77. Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, Iyer S and Smulson M. Role of poly(ADPribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem. 1999; 274: 22932-22940.
78. Noulsri E, Richardson DR, Lerdwana S, Fucharoen S, Yamagishi T, Kalinowski DS and Pattanapanyasat K. Antitumor activity and mechanism of action of the iron chelator, Dp44mT, against leukemic cells. Am J Hematol. 2009; 84: 170-176.
79. Sahni S, Bae DH, Lane DJ, Kovacevic Z, Kalinowski DS, Jansson PJ and Richardson DR. The metastasis suppressor, N-myc downstream-regulated gene 1 (NDRG1), inhibits stress-induced autophagy in cancer cells. J Biol Chem. 2014; 289: 9692-9709.
80. Pfaff DW, Arnold AP, Etgen AM, Fahrbach SE and Rubin RT: Hormones, Brain and Behavior: Chapters 1-20. 1. Acad. Press, 2009.
81. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release. 2008; 132: 171-183.
82. Kratz F. Albumin, a versatile carrier in oncology. Int J Clin Pharmacol Ther. 2010; 48: 453-455.
83. Schnitzer JE and Oh P. Albondin-mediated capillary permeability to albumin. Differential role of receptors in endothelial transcytosis and endocytosis of native and modified albumins. J Biol Chem. 1994; 269: 6072-6082.
84. Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, Iglesias JL and Renschler MF. Weekly nabpaclitaxel in combination with carboplatin versus solventbased paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012; 30: 2055-2062.
85. Iwamoto T. Clinical application of drug delivery systems in cancer chemotherapy: review of the efficacy and side effects of approved drugs. Biol Pharm Bull. 2013; 36: 715-718.
86. Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M and O'Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005; 23: 7794-7803.
87. Miao Q, Xu D, Wang Z, Xu L, Wang T, Wu Y, Lovejoy DB, Kalinowski DS, Richardson DR, Nie G and Zhao Y. Amphiphilic hyper-branched co-polymer nanoparticles for the controlled delivery of anti-tumor agents. Biomaterials. 2010; 31: 7364-7375.
88. Louis-Jeune C, Andrade-Navarro MA and Perez-Iratxeta C. Prediction of protein secondary structure from circular dichroism using theoretically derived spectra. Proteins. 2012; 80: 374-381.
89. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, Sanschagrin PC and Mainz DT. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for proteinligand complexes. J Med Chem. 2006; 49: 6177-6196.
90. Kovacevic Z, Fu D and Richardson DR. The iron-regulated metastasis suppressor, Ndrg-1: identification of novel molecular targets. Biochim Biophys Acta. 2008; 1783: 1981-1992.
91. Greenwood FC, Hunter WM and Glover JS. The Preparation of I-131-Labelled Human Growth Hormone of High Specific Radioactivity. Biochem J. 1963; 89: 114-123.
92. Commisso C, Davidson SM, Soydaner-Azeloglu RG, Parker SJ, Kamphorst JJ, Hackett S, Grabocka E, Nofal M, Drebin JA, Thompson CB, Rabinowitz JD, Metallo CM, Vander Heiden MG, et al. Macropinocytosis of protein is an amino acid supply route in Ras-transformed cells. Nature. 2013; 497: 633-637.
93. Mayle KM, Le AM and Kamei DT. The intracellular trafficking pathway of transferrin. Biochim Biophys Acta. 2012; 1820: 264-281.